ID: ALA2261919

Max Phase: Preclinical

Molecular Formula: C21H23N3O3

Molecular Weight: 365.43

Molecule Type: Small molecule

Representations

Canonical SMILES:  C=Cc1ccc2c(c1)C(=O)N1CCC[C@H]1c1c(C(=O)OC(C)(C)C)ncn1-2

Standard InChI:  InChI=1S/C21H23N3O3/c1-5-13-8-9-15-14(11-13)19(25)23-10-6-7-16(23)18-17(22-12-24(15)18)20(26)27-21(2,3)4/h5,8-9,11-12,16H,1,6-7,10H2,2-4H3/t16-/m0/s1

Standard InChI Key:  YIIKQLCKNDAHHQ-INIZCTEOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 365.43

Molecular Weight (Monoisotopic): 365.1739

AlogP: 3.76

#Rotatable Bonds: 2

Polar Surface Area: 64.43

Molecular Species: NEUTRAL

HBA: 5

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 2.83

CX LogP: 3.15

CX LogD: 3.15

Aromatic Rings: 2

Heavy Atoms: 27

QED Weighted: 0.76

Np Likeness Score: -0.09

References

1. Li X, Yu J, Atack JR, Cook JM.  (2004)  Development of Selective Ligands for Benzodiazepine Receptor Subtypes by Manipulating the Substituents at Positions 3- and 7- of Optically Active BzR Ligands,  13  (5): [10.1007/s00044-004-0033-7]

Source

Source(1):

• Scientific Literature